Palvella Therapeutics, Inc.
PVLA
$23.44
-$1.13-4.60%
NASDAQ
| 12/31/2024 | 09/30/2024 | ||||
|---|---|---|---|---|---|
| Revenue | -- | -- | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | -- | -- | |||
| Cost of Revenue | -- | -- | |||
| Gross Profit | -- | -- | |||
| SG&A Expenses | -3.03% | 28.24% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -13.75% | 74.07% | |||
| Operating Income | 13.75% | -74.07% | |||
| Income Before Tax | 41.68% | -62.39% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 41.68% | -62.39% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 41.68% | -62.39% | |||
| EBIT | 13.75% | -74.07% | |||
| EBITDA | -- | -- | |||
| EPS Basic | 74.89% | -59.62% | |||
| Normalized Basic EPS | 61.27% | -62.38% | |||
| EPS Diluted | 74.89% | -59.62% | |||
| Normalized Diluted EPS | 61.27% | -62.38% | |||
| Average Basic Shares Outstanding | 92.52% | 0.00% | |||
| Average Diluted Shares Outstanding | 92.52% | 0.00% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||